This content is restricted to site members. If you are an existing user, please log in. New users may register below.
FDA approves Inflectra, a biosimilar to Remicade
The U.S. Food and Drug Administration has approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is